A dearth of new meds.

The authors looks at a study by the Tufts Center for the Study of Drug Development, which found that pharmaceutical companies are no longer producing new central nervous system medicines to treat psychiatric and neurodegenerative disorders because of the high cost involved. Topics include the length of time it takes to develop neuropsychiatric drugs, what makes these drugs so risky, and information on the Coalition Against Major Diseases and the Cures Acceleration Network.